Regarding multiple myeloma, preclinical studies have evaluated the combination of an anti-PD-L1 antibody with panobinostat [95] or other HDAC inhibitors, showing enhanced cytotoxicity [96]. Here, HDAC9 is linked to AL amyloidosis.